Ycanth®

Drug - Ycanth® (cantharidin) [Verrica Pharmaceuticals, Inc.]

August 2026

Therapeutic Area - Keratolytics

Approval criteria

  • Patient has a diagnosis of molluscum contagiosum (MC) 
  • Patient must meet an age-appropriate medically accepted indication, as defined in Section 1927 of the Social Security Act, for the requested agent; AND
  • Ycanth will be applied by a healthcare professional trained in the preparation and administration of the treatment; AND
  • Patient will NOT be using the requested agent in combination with another conventional therapy; AND
  • Patient does NOT have any FDA labeled contraindications to the requested agent AND
  • Patient has ONE of the following:
    • Tried and had an inadequate response to ONE conventional therapy (e.g., cryotherapy, curettage, podofilox); OR
    • An intolerance or hypersensitivity to ONE conventional therapy; OR
    • An FDA labeled contraindication to ALL conventional therapy

Quantity limits

  • 2 applicators per treatment session for 12 weeks

Billing for Ycanth

  • Ycanth must be billed as a professional claim

Questions?

Provider Call Center: (844) 575-7887